Innovation: Saving Lives or Shifting Landscapes

Life science innovation is undoubtedly changing the landscape as curative drugs, diagnostics and genomics deliver increasingly targeted information and therapies. Yet, are novel collaborations taking shape to drive affordable care with these insights from clinical, pharma and genomic data? Can we unlock health data for drug discovery more rapidly by going direct-to-consumers? Hear forecasts for how targeted therapies will shift players in the market and the face of care.

Host:
Toby Cosgrove, MD, Executive Advisor & former President & CEO, Cleveland Clinic

Discussion Leaders:
Olivier Brandicourt, CEO, Sanofi
David Feinberg, MD, President & CEO, Geisinger
Anne Wojcicki, Co-Founder & CEO, 23andMe

Transcript
Share:

Coming soon!

Toby Cosgrove, MD

Executive Advisor & former President & CEO
Cleveland Clinic

Delos M. Cosgrove MD, led Cleveland Clinic as president and CEO from 2004 through 2017. He now serves as an executive advisor to the $8 billion healthcare system, which includes a main campus, 10 regional hospitals, 18 family health and surgery centers, and hospitals and clinics in Florida, Nevada, Toronto, Canada, Abu Dhabi, UAE, and London (opening 2020).  Under his leadership, Cleveland Clinic became the #2 ranked hospital Full bio ›

Olivier Brandicourt

CEO
Sanofi; Board Member, PhRMA

A physician by training, Brandicourt has 28 years of global experience in the pharmaceutical industry. He joined Sanofi in April 2015 after serving as Chief Executive Officer of Bayer Healthcare AG since 2013. In this role, he was responsible for leading the company’s global portfolio across the pharmaceuticals, consumer care, animal health, and medical care businesses. Prior to Bayer Healthcare, Brandicourt worked at Pfize Full bio ›

David Feinberg, MD

President & CEO
Geisinger

Dr. David T. Feinberg is president and chief executive officer of Geisinger Health System, one of the nation’s largest health services organization known for reinventing medical care. Geisinger is an integrated healthcare system consisting of 12 hospital campuses, two research centers, the Geisinger Commonwealth School of Medicine, over 30,000 employees, 1,600 employed physicians, 420 residents and fellows, and a 551,000-membe Full bio ›

Anne Wojcicki

Co-Founder & CEO, 23andMe

Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world’s largest da Full bio ›

related interviews

Innovation: Saving Lives or Shifting Landscapes

Toby Cosgrove, MD + Olivier Brandicourt + David Feinberg, MD + Anne Wojcicki

Life science innovation is undoubtedly changing the landscape as curative drugs, diagnostics and genomics deliver increasingly targeted information and therapies. Hear forecasts for how targeted therapies will shift players in the market and the face of care.